BiondVax – executive interview

Published on 16 August 2022

BiondVax (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Dalit Weinstein Fischer, head of technical R&D at BiondVax, discusses the company’s NanoAb development process and BiondVax’s GMP manufacturing facility.

Share this with friends and colleagues